Zb4akriywygwt6zfnjvd

Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology

Press Releases   •   Sep 21, 2016 10:43 EDT

Olink Proteomics today announced that Proseek® Multiplex Immuno-Onc I, the broadest protein biomarker panel targeting critical biological process related to immunotherapy, is now available for immediate delivery. Developed to meet a clearly expressed need from customers, the panel is designed to help companies, scientists and clinicians working with immunotherapy-based approaches to treat cancer.

Errqbxyrkks1awcxvuge

Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

Press Releases   •   May 31, 2016 06:29 EDT

Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.

Media no image

Focusing for success: A new Olink company organization to meet our future ambitions

Press Releases   •   Apr 12, 2016 08:00 EDT

Uppsala, Sweden, April 12, 2016 - Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

Olink Proteomics will continue to expand and develop the Proseek® Multiplex product line for human protein biomarker discovery. With all the company’s resources fully dedicated towards this flagship precision proteomics platform, Olink Proteomics aims to provide its customers with an ever-expanding range of high quality multiplex immunoassays for biomarker discovery, and support the future development of diagnostic tools based on clinically relevant protein signatures. This singular focus on Proseek demonstrates Olink Proteomics’ absolute commitment to provide the best possible solutions for our current and future customers in the protein biomarker field.

The CEO for Olink Proteomics AB is Lotta Falck

Email:lotta.falck@olink.com

Web: www.olinkproteomics.com

Phone +46 702 71 01 07

Olink Bioscience will focus on developing and commercializing the many additional technologies held within Olink's extensive and growing, diverse IP portfolio. With a strong R&D team dedicated to developing these new technologies in collaboration with scientists at Uppsala University, Olink Bioscience aims to continue its successful work providing access to new and innovative molecular tools for life science researchers and for molecular diagnostics.

The CEO for Olink Bioscience is Peter Åsberg

Email:peter.asberg@olinkbioscience.com

Web:www.olinkbioscience.com

Phone +46 709 49 17 21

This reorganization of Olink’s wider business will enable each of the two new companies to focus 100% on its primary objective, with fully dedicated resources and a clear sense of direction.

“The company division reflects both the desire to best serve the needs and expectations of customers in our rapidly growing Proseek business, and the deep seated commitment to develop exciting new molecular tools for the wider scientific community. Both of these can now be pursued with total focus and without compromise” say Andrea Ballagi, VP Sales & Marketing at Olink Proteomics and Peter Åsberg, CEO at Olink Bioscience.

If you have questions about this reorganization, please contact Magnus Eriksson, Chief Financial Officer, Olink Proteomics:

E-mail: magnus.eriksson@olink.com

Phone +46 18 444 39 70

Product and technology information
Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules, which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective target protein. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity, enabling Proseek Multiplex to achieve a combination of high multiplexing and excellent data quality that cannot be matched using standard immunoassay techniques. An animation illustrating how the technology works and what it is used for can be viewed on our YouTube channel.

For research use only. Not for use in diagnostic procedures.

Olink Proteomics and Olink Bioscience are headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are registered trademarks of Olink AB.

Uppsala, Sweden, April 12, 2016 - Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

Read more »
Media no image

Olink Bioscience introduces a new precision proteomics solution for neurology

Press Releases   •   Jan 27, 2016 06:50 EST

Uppsala, Sweden, January 27, 2016 - Olink Bioscience today launched Proseek® Multiplex Neurology I96x96 a new human protein biomarker panel that targets research into neurobiology and neurological diseases. This latest development of the Proseek platform expands the library of unique biomarkers available to over 440 in total, and opens up Olink’s innovative precision proteomics offering into a new and exciting field.

Neurological diseases represent a massive and growing challenge for global healthcare, with more than one billion people worldwide suffering from the consequences of neurological diseases. The long term disability that characterizes these disorders places a huge burden on healthcare resources, and a rapidly aging population continues to accelerate the problem. Estimates for Europe alone in 2010 suggested that the direct healthcare costs for neurological disorders were of the order of 300 billion EUR.

Proseek Multiplex Neurology I96x96 is designed to help scientists discover multiple neurology-related protein biomarkers and identify and verify clinically relevant protein signatures (characteristic expression patterns based on multiple proteins) that could make a significant and meaningful contribution towards meeting this huge healthcare challenge. This could pave the way for a better understanding and diagnosis of neurological disorders, and better targeted treatment for patients.

“Olink has already made an important contribution to protein biomarker discovery in key areas such as cardiovascular disease and cancer, and we are delighted to be able to extend our Proseek offering to neurologists around the world. We believe that this new panel can play an important role in improving our understanding and treatment of neurological disorders, which have huge healthcare, social and economic impacts across the Globe. With the launch of this new panel, we are offering neurologists a powerful tool to quickly and effectively measure many relevant biomarkers simultaneously and identify clinically-relevant protein signatures. In the relatively near future, our customers would like to use such information to develop and validate smaller diagnostic panels that can be used to make important clinical decisions and facilitate more effective treatments, tailored to the individual’s needs. Olink will continue to develop in-line with our customers’ requirements, and we intend to partner them all the way, from larger-scale biomarker discovery through the development of validated clinical panels and the implementation of precision medicine” says Andrea Ballagi, VP Sales & Marketing at Olink Bioscience.

What the scientists say
“Olink's neurology panel is a unique tool to find new biomarkers and gain a better understanding of the pathophysiology of neurological diseases, including pain research”, says Torsten Gordh, Professor of Clinical Pain Research at Uppsala University’s Department of Surgical Sciences.

“Olink's panels require such a small volume of material that it is now possible to analyze temporal profiles of multiple biomarkers of complex disease processes that would be very difficult to examine with other techniques” says Lars Hillered, Professor of Neurochemistry at Uppsala University’s Department of Neuroscience.

Product and technology information
Proseek Multiplex Neurology I96x96 offers high-throughput multiplex immunoassays that measure 92 neurology-related proteins across 96 samples simultaneously using only one microliter of serum, plasma, cerebrospinal fluid, or almost any other type of biological sample. Using Proseek Multiplex, thousands of samples per week can be analyzed, which greatly accelerates the speed of protein biomarker research.

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables Proseek Multiplex to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s YouTube channel.

For research use only. Not for use in diagnostic procedures.

About Olink Bioscience
Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Bioscience aims to provide outstanding products and services for human protein biomarker research and development. Our groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our Proseek® Multiplex immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each Proseek Multiplex panel is focused on a specific area of disease or biology, targeting 92 validated and exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain Proseek Multiplex as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Proseek Multiplex Analysis Service.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are trademarks or registered trademarks of Olink AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com

Uppsala, Sweden, January 27, 2016 - Olink Bioscience today launched Proseek® Multiplex Neurology I 96x96 a new human protein biomarker panel that targets research into neurobiology and neurological diseases. This latest development of the Proseek platform expands the library of unique biomarkers and opens up Olink’s innovative precision proteomics offering into a new and exciting field.

Read more »
Media no image

Olink Bioscience introduces a new 92-protein biomarker panel for oncology research

Press Releases   •   Dec 02, 2015 07:44 EST

Uppsala, Sweden, December 2, 2015 - Olink Bioscience today launched Proseek® Multiplex Oncology II96x96 a new human protein biomarker panel that targets the cancer research area. This is part of the on-going development of the Proseek platform, expanding the library of unique biomarkers available and complementing the existing panels directed against cardiovascular and inflammatory diseases. With the launch of this new panel, Olink can now provide more than 350 unique protein biomarker assays, and this offering will be significantly expanded in early 2016 with a panel focused on the clinically important field of neurology.

Proseek Multiplex Oncology II96x96 will be an important tool in the search for new protein signatures (expression patterns based on the measurement of multiple proteins) that could be used to improve the understanding, prediction and prognosis of cancer, the discovery of new drug targets, and in the development of more effective and personalized therapy for future patients. Cancer is still one of the major causes of death and continues to require massive global research efforts. Complementing and enhancing the valuable contributions made by extensive genome-based studies in the cancer field, the ability to discover and validate more protein biomarkers is likely to be increasingly important in addressing this huge healthcare challenge.

“Global healthcare has to move towards more effective strategies where the appropriate treatments are selected for the individuals who will respond best to a specific therapeutic option (often called personalized or precision medicine). This is clearly the future of medicine, but achieving it requires effective ways to identify and stratify the patients so that clinicians understand how they will respond to any given treatment. By rapidly and accurately measuring many protein biomarkers simultaneously from small volumes of patient samples, Proseek Multiplex has enormous potential to become a valuable tool in these exciting developments for future healthcare improvements. The real journey towards precision medicine is just beginning, and Olink plans to be the partner of choice for those driving this revolution, every step of the way” says Andrea Ballagi, VP Sales & Marketing at Olink Bioscience.

Product and technology information
Proseek Multiplex Oncology II96x96 offers high-throughput multiplex immunoassays that measure 92 cancer-related proteins across 96 samples simultaneously using only one microliter of serum, plasma, or almost any other type of biological sample. This panel replaces and improves on our successful Proseek Multiplex Oncology I v296x96 panel, offering 60 completely new oncology-focused biomarker assays. The composition of the panel was designed to maximize the number of useful oncology markers, as well as the overall performance of the assays. Using Proseek Multiplex, researchers can analyze thousands of samples per week, which greatly accelerates the speed of protein biomarker research.

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables Proseek Multiplex to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s YouTube channel.

For research use only. Not for use in diagnostic procedures.

About Olink Bioscience
Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Bioscience aims to provide outstanding products and services for human protein biomarker research and development. Our groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our Proseek® Multiplex immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each Proseek Multiplex panel is focused on a specific area of disease or biology, targeting 92 validated and exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain Proseek Multiplex as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Proseek Multiplex Analysis Service.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are trademarks or registered trademarks of Olink AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com

Uppsala, Sweden, December 2, 2015 - Olink Bioscience today launched Proseek® Multiplex Oncology II96x96 a new human protein biomarker panel that targets the cancer research area. With the launch of this new panel, Olink can now provide more than 350 unique protein biomarker assays. This offering will be significantly expanded in early 2016 with a panel focused on the field of neurology.

Read more »
Media no image

Olink Bioscience introduces two new 92-protein biomarker panels for cardiovascular disease research

Press Releases   •   Oct 06, 2015 08:21 EDT

Uppsala, Sweden, October 6th, 2015 – Olink Bioscience today launched Proseek® Multiplex CVD II 96x96 and Proseek Multiplex CVD III96x96, two new protein biomarker panels that target a wide range of cardiovascular-related diseases (CVDs). These panels replace and expand on our highly successful Proseek Multiplex CVD I96x96 panel, doubling the number of CVD-associated biomarkers that can be assayed, to 184. In addition to significantly expanding the number of available markers for CVD applications, the markers have been carefully selected to broaden the dynamic range for each panel and further improve assay performance and analysis.

These products are part of the on-going development of new panels, complementing the existing options directed against Oncology and Inflammatory diseases. Proseek Multiplex CVD II96x96 and Proseek Multiplex CVD III96x96 will be important tools in the search for new protein expression patterns that could serve as biomarkers to improve prediction and prognosis of CVDs, as well as discovery of new drug targets.

Cardiovascular disease is the number one cause of death worldwide and a growing health problem that requires massive medical intervention each year. Reversing this trend requires, apart from healthier lifestyles, improved diagnostic and prognostic tools. New and relevant protein biomarkers are essential components of these tools and therefore a pre-requisite for developing improved and personalized treatment. By doubling the number of CVD-related biomarkers that could be addressed with the original panel, these new products should have a significant impact in this field.

“We are excited by this opportunity to offer an expanded and further improved biomarker discovery solution for cardiovascular disease research. Our first Proseek Multiplex CVD panel set the standard for pre-validated protein biomarker assays targeted towards cardiovascular disease and has been used very successfully to publish interesting findings, with many more papers also in preparation. Our new panels will significantly enhance these capabilities and enable scientists to make more comprehensive studies, by measuring many more protein biomarkers simultaneously and over a broader dynamic range of expression levels than was previously possible. As a company, our aim is to become the preferred partner for researchers involved in protein biomarker screening studies. We sincerely hope that with these new products, we can contribute towards a better understanding of cardiovascular disease and improved and more personalized treatment.” says Andrea Ballagi, VP Sales & Marketing at Olink Bioscience.

Proseek Multiplex CVD II96x96 and Proseek Multiplex CVD III96x96 are high-throughput multiplex immunoassays that each measure 92 CVD-related proteins across 96 samples (including controls) simultaneously using only one microliter of serum, plasma, or almost any other type of biological sample. When used in combination with Fluidigm’s Biomark TM HD system, a high throughput real-time PCR platform, it enables researchers to analyze thousands of samples per week, which greatly accelerates the speed of protein biomarker research.

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables Proseek Multiplex to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques.

For research use only. Not for use in diagnostic procedures.

About Olink Bioscience

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Bioscience aims to provide outstanding products and services for human protein biomarker research and development. Our groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our Proseek® Multiplex immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each Proseek Multiplex panel is focused on a specific area of disease or biology, targeting 92 validated and exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain Proseek Multiplex as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Proseek Multiplex Analysis Service.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are trademarks or registered trademarks of Olink AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com

Uppsala, Sweden, October 6th, 2015 – Olink Bioscience today launched Proseek® Multiplex CVD II96x96 and CVD III96x96, two new protein biomarker panels that target a wide range of cardiovascular-related diseases (CVDs). These panels replace and expand on our highly successful Proseek Multiplex CVD I96x96 panel, doubling the number of CVD-associated biomarkers that can be assayed, to 184.

Read more »
Media no image

Olink Bioscience introduces a 92-protein biomarker panel for inflammatory diseases

Press Releases   •   Jul 01, 2014 07:55 EDT

Uppsala, Sweden, July 1st, 2014 – Molecular tools specialist Olink Bioscience today launched Proseek® Multiplex Inflammation I 96x96, a new protein biomarker panel that targets a wide range of inflammatory diseases. This panel complements the existing panels directed against Oncology and Cardiovascular diseases in a growing collection. Proseek Multiplex Inflammation I 96x96 will be an important tool in the search for new multivariate protein expression patterns that could serve as biomarkers to improve prediction and prognosis of inflammatory diseases, as well as discovery of new drug targets.

Inflammatory mechanisms are involved in many types of diseases where the immune system creates a chronic inflammation often resulting in functional impairment of organs. Rheumatoid arthritis, multiple sclerosis, psoriasis, irritable bowel diseases, and asthma are examples of such diseases. The inflammatory response also plays a major role in other diseases such as cardiovascular disorders, cancer, diabetes and Alzheimer’s disease. Chronic immune system disorders affect millions of people every year, and there is a great unmet need in predicting the efficacy of treatment options at individual level. It is crucial to find new biomarkers to meet these needs in personalized medicine but also for better healthcare in general through improving diagnostic and prognostic tools.

“With the launch of our next exciting multiplex immunoassay panel we are another step closer to the vision of identifying protein profiles that will change the way we prevent, diagnose and treat diseases. Proseek Multiplex makes anyone with access to biological material able to screen for protein biomarker profiles in an exceptionally efficient way.” says Andrea Ballagi, Chief Operating Officer at Olink Bioscience.

Proseek Multiplex Inflammation I 96x96 is a high throughput multiplex immunoassay that efficiently measures 92 inflammation-related proteins across 96 samples (including controls) simultaneously in only one microliter of serum or plasma. When used in combination with Fluidigm’s Biomark TM HD system, a high throughput real-time PCR platform, it enables researchers to analyze thousands of samples per week, which greatly accelerates the speed of discovery of new protein biomarkers. 

“We are very pleased with the initial results obtained with Proseek Multiplex Inflammation I 96x96. We have already found several interesting biomarker candidates and we will now extend our study to compare the results with other available panels. Proseek Multiplex Inflammation I 96x96 is certainly a promising tool for future use in rheumatoid arthritis” say Professor Lars Klareskog and Assoc.Prof. Anca Catrina, Rheumatology clinic and research unit, Karolinska University Hospital and Karolinska Institutet,

The Proseek Multiplex Inflammation I 96x96 panel comprises established inflammatory markers as well as a few proteins with great potential to become new biomarkers for inflammatory disorders. The content of the panel has been designed in close collaboration with experts in various inflammatory disease fields such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, neuro inflammation, and respiratory diseases. The panel is therefore well suited to elucidating protein expression profiles in clinically relevant samples. Proseek Multiplex Inflammation I 96x96 is the third panel from Olink Bioscience. 

Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

For research use only. Not for use in diagnostic procedures.

About Olink Bioscience
Olink Bioscience produces innovative products for biomarker research and development. Our goal is to help our customers and collaborators improve clinical decisions through the use of molecular biomarkers. Our groundbreaking tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and industry with over 700 customer publications. Proseek Multiplex is a next generation multivariate protein biomarker detection kit. It allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 92 proteins in just 1 microliter liquid sample, such as serum and plasma, with exceptional analytical performance.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are trademarks or registered trademarks of Olink AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
Director Commercial Operations
Phone: +46-18-444 3970
E-mail: info@olink.com


Uppsala, Sweden, July 1st, 2014 – Olink Bioscience today launched Proseek® Multiplex Inflammation I 96x96, a new protein biomarker panel targeting inflammatory diseases. This product will be an important tool in the search for multivariate protein expression patterns that could serve as biomarkers to improve prediction and prognosis of inflammatory diseases, and to discover new drug targets.

Read more »
Media no image

A new European Consortium to improve therapeutic guidance for patients with metastatic breast cancer

Press Releases   •   Dec 04, 2013 09:39 EST

The CareMore* Consortium is a collaborative effort to advance diagnostic systems for therapy guidance in patients with metastatic breast cancer. The consortium associates five European partners from both academia and industry, and launches with a € 5M grant via the European Commission´s 7th Framework Program (FP7**).

Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour, while 90% of deaths due to breast cancer occur as a consequence of metastases. In up to 50% of all breast cancer patients the molecular profile of the metastasis is different from the primary tumour that is currently guiding treatment. The CareMore project will develop and clinically validate a system to guide treatment decisions in women with metastatic breast cancer based on molecular characterization of circulating tumour cells (CTCs), used as proxies for the metastatic tumour. 

Two unique methods will be combined, single cell-based in situ detection of genetic mutations and protein expression and improved CTC sampling and identification, provided by the participating small and medium sized enterprises (SMEs) Olink Bioscience and CytoTrack. Together with leading academic scientists at Erasmus MC Cancer Institute and Stockholm University and Philips, a strong industrial partner and leader in diagnostic imaging, the consortium aims to establish the clinical utility of the proposed approach.

"We are very pleased to have gathered such a strong team.” said Dr. Mats Gullberg, project coordinator for CareMore and Chief Technology Officer at Olink Bioscience. "The project offers a tremendous opportunity to advance our current ability to choose the correct treatment for each individual patient. While we anticipate heavy competition from standard immuno-staining methods we see a distinct competitive advantage in scoring genetic parameters in the same cell simultaneously. In view of the evident need of visual inspection for CTC identification, our proposed in situ molecular characterization assay has the potential to provide the most robust and cost effective approach for companion diagnostic based on CTCs."

A successful outcome of the CareMore project approach is expected to be readily replicated to other cancer types in which molecular classification is used for therapy guidance.

Consortium members
The project will be coordinated by Olink Bioscience (Sweden) with partners from the Netherlands, Denmark and Sweden. The CareMore Consortium unites researchers from two SME’s, two universities and one large industry. 

CareMore is a three-year project running from the 1st of September 2013 until the 30th of August 2016 and is funded by the 7th Framework Program of the European Commission. In addition to the research activities, CareMore will be organizing meetings, workshops and will be present at a number of international conferences.

Members of the consortium:

  • Olink Bioscience (Coordinator, SME), Mats Gullberg, SE
  • CytoTrack , Tom Hede Markussen, DK
  • Erasmus MC Cancer Institute, Stefan Sleijfer, NL
  • Philips Electronics Nederland B.V. Reinhold Wimberger-Friedl, NL
  • Stockholms Universitet, Mats Nilsson, SE

Contact
Dr. Mats Gullberg: +46-70-9428520, Mats.Gullberg@olink.com 
Dr. Ida Grundberg: +46-18-4443994, Ida.Grundberg@olink.com
CareMore website: www.CareMoreCTC.eu

* CareMore is the acronym to the project´s full title “Cancer Responsiveness Monitoring based on Resistance mutations in CTCs”.

** FP7 is the short name for the Seventh Framework Programme for Research and Technological Development. This is the EU's main instrument for funding research in Europe and it will run from 2007-2013.

The CareMore* Consortium is a collaborative effort to advance diagnostic systems for therapy guidance in patients with metastatic breast cancer. The consortium associates five European partners from both academia and industry, and launches with a € 5M grant via the European Commission´s 7th Framework Program (FP7**).

Read more »
Media no image

Olink Bioscience introduces a 92 protein biomarker panel for cardiovascular disease

Press Releases   •   Oct 29, 2013 08:57 EDT

Uppsala, Sweden, October 29, 2013 – Olink Bioscience today launches Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease. This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Cardiovascular disease is the number one cause of death worldwide and a growing health problem that requires massive medical intervention each year. Reversing this trend requires, apart from healthier lifestyles, improved diagnostic and prognostic tools. New and relevant protein biomarkers are essential components of these tools and therefore a pre-requisite for developing improved and personalized treatment. 

Proseek Multiplex CVD I 96x96 is a high throughput multiplex immunoassay which speedily allows analysis of 92 cardiovascular-related protein biomarkers across 96 samples simultaneously without any compromise in data quality. Only one microliter of sample is required, economizing on precious or biobanked clinical material. When used in conjunction with Fluidigm’s BioMark HD System, Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market today. Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time. Using the BioMark HD System with the Proseek Multiplex CVD I 96x96, a researcher can now obtain results for up to 9,216 reactions in just a few hours.

“It is a very exciting opportunity when Olink can offer a new tool for researchers, clinicians and anyone interested in cardiovascular diseases. It’s well known that all individuals are different and in an ideal world could receive personalized medicine and care. We would like to contribute to fulfilling that dream faster by helping to find new protein expression patterns that could serve as biomarkers” says Andrea Ballagi, Director Commercial Operations at Olink Bioscience.

The Proseek Multiplex CVD I 96x96 panel contains known cardiovascular and inflammatory markers as well as a few exploratory proteins which have great potential as new cardiovascular markers. The exploratory markers are intracellular proteins which were unexpectedly detected in serum or plasma samples, demonstrating that Proseek Multiplex is a sensitive tool for analyzing proteins in body fluids.

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach. The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level -- and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR.

“The cardiovascular panel has already attracted a lot of interest among cardiovascular researchers; we have many customers knocking on our door eager to start analyzing their own clinical samples. We have already performed some initial testing of the panel and the results look very promising. We are very excited about the possibilities Proseek Multiplex CVD I 96x96 offers to the cardiovascular research community and pharmaceutical industry” says Agneta Siegbahn, Professor in Clinical Coagulation Science, Department of Medical Sciences, Uppsala University and Managing Director of Clinical Biomarkers Facility at Science for Life Laboratory in Uppsala, Uppsala University, one of Olink’s service providers.

Proseek Multiplex is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

Proseek Multiplex CVD I 96x96 is the second panel from Olink. The company has launched the Proseek Multiplex Oncology I 96x96 product previously this year. Both are for research use only.

About Olink 

Olink Bioscience produces innovative products for biomarker research and development. Our goal is to help our customers and collaborators to improve clinical decisions through the use of molecular biomarkers. Our groundbreaking tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and industry with over 700 customer publications. Proseek Multiplex is a next generation multivariate protein biomarker detection kit. It allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 92 proteins in just 1 microliter liquid sample, such as serum and plasma, with exceptional analytical performance.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink AB and Proseek are trademarks or registered trademarks of Olink Bioscience.

Contact information
Andrea Ballagi, MD, PhD, MBA
Director Commercial Operations
Phone: +46-18-444 3970
E-mail: info@olink.com

Uppsala, Sweden, October 29, 2013 – Olink Bioscience today launches Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease. This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Read more »
Media no image

Fluidigm and Olink Bioscience Bring a New Level of Protein Biomarker Discovery to the Life Science Research Market - 96 Samples Across 92 Proteins in One Microfluidic Run

Press Releases   •   Jul 31, 2013 09:12 EDT

UPPSALA, Sweden and SOUTH SAN FRANCISCO, Calif., USA -- July 31, 2013 -- Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day.

The two companies will co-market the combination of their respective products --  Fluidigm’s BioMarkTM HD System and Olink Bioscience’s Proseek® Multiplex technology -- bringing protein research to the Fluidigm platform and Olink Bioscience’s protein detection assays to the high-throughput, high reproducibility and unparalleled sensitivity realm of Fluidigm’s real-time PCR system. 

Fluidigm’s BioMark HD System and Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market today.  Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time.  Using the BioMark HD System with the Proseek Multiplex Oncology I 96x96 Kit, a researcher can simultaneously analyze 96 human samples against a panel of 92 analytes, such as growth factors, inflammatory markers, soluble receptors, or cancer antigens. With the addition of four control analytes (two incubation controls, and extension and detection controls), researchers can now obtain results for up to 9,216 reactions in just a few hours. 

The first 92-plex Olink panel, available now, is focused on biomarker discovery for cancer. Panels addressing cardiovascular disease and inflammation are expected to be offered later this year.

“Protein research is so important because these biomarkers are used to monitor health states and predict treatment outcomes in patients. One of the biggest trends in the life sciences industry today is research to uncover biomarkers that can lead to companion diagnostics," said Simon Fredriksson, Olink Bioscience president and chief executive officer. “Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity when more and more assays are run simultaneously. Olink’s Proseek Multiplex generates high quality data even in highly multiplexed formats, and using these assays in conjunction with Fluidigm’s BioMark HD System gives protein researchers easy access to unprecedented volume and quality of data.” 

The Olink Bioscience assay provides a signal when pairs of antibodies equipped with DNA reporter molecules bind to their targets to create new DNA amplicons. The amplicons are subsequently quantified by high throughput real-time PCR. With PCR’s large dynamic range and superb sensitivity, in combination with Olink Bioscience’s unique protein detection assays, the opportunities are enormous for powerful analysis of multivariate biomarker patterns. 

“Analyzing 92 proteins from one microliter of sample enables new biomarker discovery and validation,” said Gajus Worthington, Fluidigm president and chief executive officer. “Many sample sources, including those from biorepositories or model organisms, are limited, and researchers can simply run out before they are able to find useful biomarker panels.  The combination of Fluidigm’s BioMark HD System and Olink’s Proseek Multiplex assay represents a robust new tool for the protein research community." 

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach. The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level -- and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR. 

Olink Bioscience's Proseek Multiplex is a multivariate protein biomarker detection kit based on Olink’s proprietary Proximity Extension Assay (PEA). It uniquely allows multiplexing of immunoassays without compromising assay performance. PEA uses pairs of oligonucleotide-labeled antibodies equipped with DNA reporter molecules to bind to proteins of interest in a highly specific manner, solving the antibody cross-reactivity dilemma that plagues and limits conventional protein assays. 

About Olink Bioscience
Olink Bioscience develops, manufactures, and markets unique and highly innovative proprietary products for biomarker research and development. Together with their customers and collaborators they aim to improve clinical decision making by the use of molecular biomarkers. Their groundbreaking tools gain new insights in disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In Situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and pharmaceutical industry with over 700 customer publications. Proseek Multiplex is a next generation multivariate protein biomarker detection kit. It uniquely allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 92 proteins in just 1 μL liquid samples, such as serum and plasma, with exceptional analytical performance.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink AB and Proseek are trademarks or registered trademarks of Olink Bioscience. 

About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including 13 different commercial IFCs for nucleic acid analysis, and three families of assay chemistries. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm products are provided: For Research Use Only. Not for use in diagnostic procedures.

For more information, please visit www.fluidigm.com. 

Fluidigm, the Fluidigm logo, and BioMark are trademarks or registered trademarks of Fluidigm Corporation. 

Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Fluidigm’s product and marketing plans, development, objectives, expectations and/or strategies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, marketing, and selling products.  Information on these and additional risks affecting Fluidigm’s business and operating results are contained in its filings with the Securities and Exchange Commission, including its most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements.

Contact:
Howard High
Fellow, Corporate Communications and Press Relations
Fluidigm Corporation
650-266-6081 (office)
510-786-7378 (mobile)
howard.high@fluidigm.com

Simon Fredriksson, Ph.D. 
Olink AB 
Phone: +46 18 444 3970 
E-mail: info@olink.com

Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day. The two companies will co-market the combination of their respective products -- Fluidigm’s BioMarkTM HD System and Olink Bioscience’s Proseek® Multiplex technology.

Read more »

Images & Videos 3 images, 2 videos

Contacts 2 contacts

  • Press Contact
  • Marketing Communications Manager
  • Marketing Communications
  • garyls.franklin@hwolink.yllqcodlm
  • +46722518330
  • +46722518330

About Olink Proteomics

Swedish company Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery.

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics provides outstanding products and services for human protein biomarker research. We help scientists get answers quickly and confidently through robust, multiplex biomarker analysis. Proseek® Multiplex immunoassay panels enable rapid, high-throughput analysis, with exceptional data quality and minimal sample consumption. Using just 1 µl of sample, 92 biomarkers are assayed simultaneously, with up to 96 samples run per panel. Our Proximity Extension Assay (PEA) technology enables this high level of multiplexing, as this dual recognition, DNA-coupled method provides exceptional readout specificity. Disease area-focused panels have both validated and exploratory biomarkers, selected in collaboration with leading experts, and our rigorous assay validation data is freely available. Choosing either ready-to-use kits or our Proseek Multiplex Analysis Service, customers get high quality data and rapid high-throughput analysis that makes the most effective use of their precious samples.

Olink Proteomics is headquartered in Uppsala, Sweden and also has an office and service laboratory for its US regional organization, based in Watertown MA.

Address

  • Olink Proteomics
  • Dag Hammarskjölds väg 52 B
  • 752 37 Uppsala
  • Our homepage

Links